Recombinant Vaccine Against Porcine Circovirus Type 2

Recombinant porcine circovirus type 2 vaccine (PCV2), based on a chimeric variant of the CAP protein, which is boosted with an immunomodulator.

Advantages

This vaccine has shown to be able to control subclinical infection, taking the viral load to indetectable by qPCR assay. Current commercial anti-PCV2 vaccines are based on immunogens, which generate neutralizing antibodies that control the clinical course of the disease, but have not been able to control subclinical infection, maintaining viral infection in the swine population and the threat of resurgence. of clinical disease.